Next Article in Journal
10-Year Renal Function Trajectories in Community-Dwelling Older Adults: Exploring the Risk Factors for Different Patterns
Previous Article in Journal
The Vagus Nerve Can Predict and Possibly Modulate Non-Communicable Chronic Diseases: Introducing a Neuroimmunological Paradigm to Public Health
Open AccessArticle

Bone Metabolism Markers and Bone Mineral Density in Patients on Long-Term Acenocoumarol Treatment: A Cross-Sectional Study

1
Department of Family Medicine, Medical University of Bialystok, Bialystok 15-054, Poland
2
Department of Haematology, Medical University of Bialystok, Bialystok 15-276, Poland
3
Department of Immunology, Medical University of Bialystok, Bialystok 15-269, Poland
4
Department of Pediatric Rheumatology, Immunology, and Metabolic Bone Diseases, Medical University of Bialystok, Bialystok 15-274, Poland
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2018, 7(10), 372; https://doi.org/10.3390/jcm7100372
Received: 10 October 2018 / Revised: 17 October 2018 / Accepted: 18 October 2018 / Published: 20 October 2018
(This article belongs to the Section Pharmacology)
The aim of this study was to evaluate levels of osteocalcin (OC), osteoprotegerin (OPG) and total soluble receptor activator of nuclear factor-κB ligand (RANKL), and bone mineral density (BMD) in patients on long-term acenocoumarol (AC) treatment. The cross-sectional study was carried out in 42 patients treated long-term with AC and 28 control subjects. Serum concentrations of OC, OPG, and sRANKL were measured using enzyme linked immunosorbent assay (ELISA) kits, and BMD at the femoral neck and lumbar spine were assessed by dual energy X-ray absorptiometry. A significantly decreased concentration of OC was found in AC users compared to control subjects (4.94 ± 2.22 vs. 10.68 ± 4.5; p < 0.001). Levels of OPG, sRANKL logarithm (log), sRANKL/OPG log ratio, and BMD were comparable between. In female AC users, positive correlations between OC and RANKL log, and between OC and RANKL/OPG log ratio (p = 0.017; p = 0.005, respectively), and a negative correlation between OC and OPG (p = 0.027) were found. Long-term AC anticoagulation significantly decreases OC concentration, but does not affect other bone metabolism markers or BMD. Our results also suggest the possibility that long-term treatment with AC may alleviate bone resorption in postmenopausal women. View Full-Text
Keywords: acenocoumarol; bone mineral density; bone metabolism; osteocalcin; vitamin K antagonists acenocoumarol; bone mineral density; bone metabolism; osteocalcin; vitamin K antagonists
Show Figures

Figure 1

MDPI and ACS Style

Sawicka-Powierza, J.; Jablonska, E.; Ratajczak-Wrona, W.; Rogowska-Szadkowska, D.; Garley, M.; Oltarzewska, A.M.; Chlabicz, S.; Konstantynowicz, J. Bone Metabolism Markers and Bone Mineral Density in Patients on Long-Term Acenocoumarol Treatment: A Cross-Sectional Study. J. Clin. Med. 2018, 7, 372.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop